Testing a Promising Remyelinating Agent for Relapsing-Remitting Multiple Sclerosis: The VISTA Trial

Relapsing-remitting multiple sclerosis (RRMS) is the most prevalent form of multiple sclerosis (MS). A defining feature of all MS types is the presence of demyelinating lesions in the brain and spinal cord. In healthy neurons, myelin, a specialized extension of the oligodendrocyte plasma membrane, acts as an insulator, enabling rapid and efficient conduction of electrical signals along the axon. In demyelinating conditions such as MS, the loss of myelin slows signal transmission and can ultimately result in permanent impairment of neuronal function.¹